Biotechnology Law Report

Aims & Scope

Biotechnology Law Report delivers critical authoritative analysis of biotech patents and litigation, regulatory and legislative activity, and trade-related aspects of biotechnology.

As the first journal in the field of biotechnology law nearly 40 years ago, it provides exclusive access to historic developments that are informing legal cases today.

The Journal is particularly devoted to industries in which new biotechology products are developing the most rapidly: pharmaceuticals, chemicals, agriculture, food processing, energy, mineral recovery, and waste treatment.

Biotechnology Law Report is highly recommended for law firms or corporate legal department library collections contributing research services to biotechnology research or a patent law practice.

Biotechnology Law Report coverage includes: -Pharmaceutical regulatory affairs- Agricultural and environmental regulatory affairs- Patents and patent litigation- Licensing and collaborations- Financial and shareholder news- Meeting Notices

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	0.3
2024	0.20

SJR (SCImago Journal Rank)

Year	Value
2024	0.133

Quartile

Year	Value
2024	Q4

Journal Rank

Year	Value
2024	26012

Journal Citation Indicator

Year	Value
2024	19

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Environmental Science, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Amicus Brief of Myriad Genetics, Inc. in McKesson Technologies, Inc. v. Epic Sys. Corp. (Fed. Cir. No. 2010-1291)

  Citation: 119

  Authors:

• {BLR 2080} Intellectual Property - Internet

  Citation: 118

  Authors:

• FDA's Expedited Approval Mechanisms for New Drug Products

  Citation: 73

  Authors: Erin E.

• Can Unpredictable New Technology Satisfy Enablement? <i>Enzo Biochem, Inc. v. Calgene, Inc.</i>, 188 F.3d 1362 (Fed. Cir. 1999)

  Citation: 60

  Authors: Teresa

• Athena Diagonistics, Inc. v. Mayo Collaborative Servs., LLCMassachusetts District Court, 2017No. 15-CV-40075-IT, 2017 WL 3336275

  Citation: 45

  Authors:

• Guidance for Industry Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology

  Citation: 41

  Authors:

• Social and Ethical Issues in Nanotechnology: Lessons from Biotechnology and Other High Technologies

  Citation: 22

  Authors: Joel Rothstein

• Perspectives and Opportunities for Precompetitive Public–Private Partnerships in the Biomedical Sector

  Citation: 22

  Authors: H., G., B., I.

• <i>Festo v. Shoketsu Kinzoku Kogyo Kabushiki</i> (95-1066)

  Citation: 21

  Authors:

• In re Stepan Co., No. 2010-1261 (Fed. Cir. Oct. 5, 2011)

  Citation: 19

  Authors:

---